A68930 - A POTENT AGONIST SELECTIVE FOR THE DOPAMINE-D1 RECEPTOR

被引:76
作者
DENINNO, MP
SCHOENLEBER, R
MACKENZIE, R
BRITTON, DR
ASIN, KE
BRIGGS, C
TRUGMAN, JM
ACKERMAN, M
ARTMAN, L
BEDNARZ, L
BHATT, R
CURZON, P
GOMEZ, E
KANG, CH
STITTSWORTH, J
KEBABIAN, JW
机构
[1] ABBOTT LABS,DIV NEUROSCI RES,DEPT 47U,BLDG AP-10,1 ABBOTT PK RD,N CHICAGO,IL 60064
[2] UNIV VIRGINIA,DEPT NEUROL,CHARLOTTESVILLE,VA 22908
关键词
DOPAMINE-D1; RECEPTORS; A-68930 ((1R,3S)-1-AMINOMETHYL-5,6-DIHYDROXY-3-PHENYLISOCHROMAN);
D O I
10.1016/0014-2999(91)90459-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A68930, (1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman HCl, is a potent (EC50 = 2.5 nM), partial (intrinsic activity = 66% of dopamine) agonist in the fish retina dopamine-sensitive adenylate cyclase model of the D1 dopamine receptor. In the rat caudate-putamen model of the D1 dopamine receptor, A68930 is a potent (EC50 = 2.1 nM) full agonist. In contrast, A68930 is a much weaker (EC50 = 3920 nM) full agonist in a biochemical model of the dopamine D2 receptor. The orientation of the 3-phenyl substituent in the molecule is critical for the affinity and selectivity of the molecule towards the dopamine D1 receptor. A68930 also displays weak alpha-2-agonist activity but the molecule is virtually inactive at the alpha-1- and beta-adrenoceptors. When tested in rats bearing a unilateral 6-OHDA lesion of the nigro-neostriatal neurons, A68930 elicits prolonged (> 20 h) contralateral turning that is antagonized by dopamine D1 receptor selective doses of SCH 23390 but not by D2 receptor selective doses of haloperidol. In this lesioned rat model, A68930 increases 2-deoxyglucose accumulation in the lesioned substantia nigra, pars reticulata. When tested in normal rats, A68930 elicits hyperactivity and, at higher doses, produces a forelimb clonus.
引用
收藏
页码:209 / 219
页数:11
相关论文
共 37 条
  • [1] THE FUNCTIONAL-ANATOMY OF BASAL GANGLIA DISORDERS
    ALBIN, RL
    YOUNG, AB
    PENNEY, JB
    [J]. TRENDS IN NEUROSCIENCES, 1989, 12 (10) : 366 - 375
  • [2] PROCONVULSANT EFFECT OF SKF-38393 MEDIATED BY NIGRAL D1 RECEPTORS
    ALTAJIR, G
    STARR, MS
    STARR, BS
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 182 (02) : 245 - 251
  • [3] OPPOSITE EFFECTS OF STIMULATION OF D1 AND D2 DOPAMINE-RECEPTORS ON THE EXPRESSION OF MOTOR SEIZURES IN MOUSE AND RAT
    ALTAJIR, G
    CHANDLER, CJ
    STARR, BS
    STARR, MS
    [J]. NEUROPHARMACOLOGY, 1990, 29 (07) : 657 - 661
  • [4] THIENOPYRIDINE DERIVATIVES IDENTIFIED AS THE 1ST SELECTIVE, FULL EFFICACY, DOPAMINE D1 RECEPTOR AGONISTS
    ANDERSEN, PH
    NIELSEN, EB
    SCHEELKRUGER, J
    JANSEN, JA
    HOHLWEG, R
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 137 (2-3) : 291 - 292
  • [6] DOPAMINE-D1 RECEPTOR MODULATION OF PILOCARPINE-INDUCED CONVULSIONS
    BARONE, P
    PARASHOS, SA
    PALMA, V
    MARIN, C
    CAMPANELLA, G
    CHASE, TN
    [J]. NEUROSCIENCE, 1990, 34 (01) : 209 - 217
  • [7] N,N-DISUBSTITUTED 2-AMINOTETRALINS ARE POTENT D-2 DOPAMINE RECEPTOR AGONISTS
    BEAULIEU, M
    ITOH, Y
    TEPPER, P
    HORN, AS
    KEBABIAN, JW
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 105 (1-2) : 15 - 21
  • [8] LITHIUM AMPLIFIES AGONIST-DEPENDENT PHOSPHATIDYLINOSITOL RESPONSES IN BRAIN AND SALIVARY-GLANDS
    BERRIDGE, MJ
    DOWNES, CP
    HANLEY, MR
    [J]. BIOCHEMICAL JOURNAL, 1982, 206 (03) : 587 - 595
  • [9] SELECTIVE D-1 DOPAMINE RECEPTOR AGONIST TREATMENT OF PARKINSONS-DISEASE
    BRAUN, A
    FABBRINI, G
    MOURADIAN, MM
    SERRATI, C
    BARONE, P
    CHASE, TN
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1987, 68 (1-2) : 41 - 50
  • [10] TRANS-10,11-DIHYDROXY-5,6,6A,7,8,12B-HEXAHYDROBENZO[A]PHENANTHRIDINE - A HIGHLY POTENT SELECTIVE DOPAMINE-D1 FULL AGONIST
    BREWSTER, WK
    NICHOLS, DE
    RIGGS, RM
    MOTTOLA, DM
    LOVENBERG, TW
    LEWIS, MH
    MAILMAN, RB
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (06) : 1756 - 1764